CDIO vs HLIO

For growth investors, Cardio Diagnostics Holdings, Inc.

(CDIO) is the stronger pick with 104. 5% revenue growth year-over-year, versus 4. 1% for Helios Technologies, Inc. (HLIO). Helios Technologies, Inc. (HLIO) offers the better valuation at 46. 9x trailing P/E (26. 9x forward), making it the more compelling value choice. Analysts rate Cardio Diagnostics Holdings, Inc. (CDIO) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Helios Technologies, Inc.

(HLIO) delivered a total return of -8. 1%, compared to -99. 4% for Cardio Diagnostics Holdings, Inc. (CDIO). Over 10 years, the gap is even starker: HLIO returned +109. 8% versus CDIO's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Helios Technologies, Inc.

(HLIO) is the lower-risk stock at 1. 56β versus Cardio Diagnostics Holdings, Inc. 's 3. 00β — meaning CDIO is approximately 93% more volatile than HLIO relative to the S&P 500. On balance sheet safety, Cardio Diagnostics Holdings, Inc. (CDIO) carries a lower debt/equity ratio of 10% versus 12% for Helios Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cardio Diagnostics Holdings, Inc.

(CDIO) is pulling ahead at 104. 5% versus 4. 1% for Helios Technologies, Inc. (HLIO). On earnings-per-share growth, the picture is similar: Cardio Diagnostics Holdings, Inc. grew EPS 53. 0% year-over-year, compared to 23. 9% for Helios Technologies, Inc.. Over a 3-year CAGR, CDIO leads at 238. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Helios Technologies, Inc.

(HLIO) is the more profitable company, earning 5. 8% net margin versus -240. 3% for Cardio Diagnostics Holdings, Inc. — meaning it keeps 5. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HLIO leads at 7. 9% versus -239. 8% for CDIO. At the gross margin level — before operating expenses — CDIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, HLIO (0.

5% yield) pays a dividend. CDIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Helios Technologies, Inc.

(HLIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 5% yield, +109. 8% 10Y return). Cardio Diagnostics Holdings, Inc. (CDIO) carries a higher beta of 3. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HLIO: +109. 8%, CDIO: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CDIO (Healthcare) and HLIO (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CDIO is a small-cap high-growth stock; HLIO is a small-cap quality compounder stock. HLIO pays a dividend while CDIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.